Effects of 100 and 300 units of onabotulinum toxin A on lower urinary tract symptoms of benign prostatic hyperplasia: A phase II randomized clinical trial

E. David Crawford, Kathryn Hirst, John W. Kusek, Robert F. Donnell, Steven A. Kaplan, Kevin T. McVary, Lance A. Mynderse, Claus Roehrborn, Christopher P. Smith, Reginald Bruskewitz

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Purpose: We conducted a 2-stage, multicenter, double-blind, randomized phase II clinical trial of 100 and 300 unit doses of onabotulinum toxin A to treat the lower urinary tract symptoms of benign prostatic hyperplasia. Materials and Methods: Men 50 years old or older with clinically diagnosed benign prostatic hyperplasia, American Urological Association symptom index 8 or greater, maximum urinary flow rate less than 15 ml per second, voided volume 125 ml or greater, and post-void residual 350 ml or less were randomized to prostatic transrectal injection of 100 or 300 units of onabotulinum toxin A. The primary outcome was at least 30% improvement from baseline to 3 months in American Urological Association symptom index and/or maximum urinary flow rate and safety. The men were followed for 12 months. Results: A total of 134 men were randomized and treated (68 with 100 units, 66 with 300 units), with 131 assessed at 3 months and 108 assessed at 12 months. Each dose met the 3-month primary outcome criteria. In the 100 unit arm the mean baseline American Urological Association symptom index of 18.8 decreased by 7.1 and 6.9 at 3 and 12 months, respectively. In the 300 unit arm the baseline of 19.5 decreased by 8.9 and 7.1, respectively. In the 100 unit arm the mean baseline maximum urinary flow rate of 10.0 ml per second increased by 2.5 and 2.2, respectively, and in the 300 unit arm the baseline of 9.6 increased by 2.6 and 2.3, respectively. Conclusions: The intraprostatic injection of 100 or 300 units of onabotulinum toxin A passed predetermined criteria for treatment efficacy and safety, and a randomized trial with either dose is warranted. The 100 unit dose may be preferable due to similar efficacy with reduced costs and adverse effects.

Original languageEnglish (US)
Pages (from-to)965-970
Number of pages6
JournalJournal of Urology
Volume186
Issue number3
DOIs
StatePublished - Sep 2011

Fingerprint

Lower Urinary Tract Symptoms
Phase II Clinical Trials
Prostatic Hyperplasia
Randomized Controlled Trials
Safety
Injections
Costs and Cost Analysis
onabotulinumtoxinA

Keywords

  • onabotulinum toxin A
  • prostatic hyperplasia

ASJC Scopus subject areas

  • Urology

Cite this

Effects of 100 and 300 units of onabotulinum toxin A on lower urinary tract symptoms of benign prostatic hyperplasia : A phase II randomized clinical trial. / Crawford, E. David; Hirst, Kathryn; Kusek, John W.; Donnell, Robert F.; Kaplan, Steven A.; McVary, Kevin T.; Mynderse, Lance A.; Roehrborn, Claus; Smith, Christopher P.; Bruskewitz, Reginald.

In: Journal of Urology, Vol. 186, No. 3, 09.2011, p. 965-970.

Research output: Contribution to journalArticle

Crawford, ED, Hirst, K, Kusek, JW, Donnell, RF, Kaplan, SA, McVary, KT, Mynderse, LA, Roehrborn, C, Smith, CP & Bruskewitz, R 2011, 'Effects of 100 and 300 units of onabotulinum toxin A on lower urinary tract symptoms of benign prostatic hyperplasia: A phase II randomized clinical trial', Journal of Urology, vol. 186, no. 3, pp. 965-970. https://doi.org/10.1016/j.juro.2011.04.062
Crawford, E. David ; Hirst, Kathryn ; Kusek, John W. ; Donnell, Robert F. ; Kaplan, Steven A. ; McVary, Kevin T. ; Mynderse, Lance A. ; Roehrborn, Claus ; Smith, Christopher P. ; Bruskewitz, Reginald. / Effects of 100 and 300 units of onabotulinum toxin A on lower urinary tract symptoms of benign prostatic hyperplasia : A phase II randomized clinical trial. In: Journal of Urology. 2011 ; Vol. 186, No. 3. pp. 965-970.
@article{4e64ea9b4de04a72bd9bd4c66f8abad2,
title = "Effects of 100 and 300 units of onabotulinum toxin A on lower urinary tract symptoms of benign prostatic hyperplasia: A phase II randomized clinical trial",
abstract = "Purpose: We conducted a 2-stage, multicenter, double-blind, randomized phase II clinical trial of 100 and 300 unit doses of onabotulinum toxin A to treat the lower urinary tract symptoms of benign prostatic hyperplasia. Materials and Methods: Men 50 years old or older with clinically diagnosed benign prostatic hyperplasia, American Urological Association symptom index 8 or greater, maximum urinary flow rate less than 15 ml per second, voided volume 125 ml or greater, and post-void residual 350 ml or less were randomized to prostatic transrectal injection of 100 or 300 units of onabotulinum toxin A. The primary outcome was at least 30{\%} improvement from baseline to 3 months in American Urological Association symptom index and/or maximum urinary flow rate and safety. The men were followed for 12 months. Results: A total of 134 men were randomized and treated (68 with 100 units, 66 with 300 units), with 131 assessed at 3 months and 108 assessed at 12 months. Each dose met the 3-month primary outcome criteria. In the 100 unit arm the mean baseline American Urological Association symptom index of 18.8 decreased by 7.1 and 6.9 at 3 and 12 months, respectively. In the 300 unit arm the baseline of 19.5 decreased by 8.9 and 7.1, respectively. In the 100 unit arm the mean baseline maximum urinary flow rate of 10.0 ml per second increased by 2.5 and 2.2, respectively, and in the 300 unit arm the baseline of 9.6 increased by 2.6 and 2.3, respectively. Conclusions: The intraprostatic injection of 100 or 300 units of onabotulinum toxin A passed predetermined criteria for treatment efficacy and safety, and a randomized trial with either dose is warranted. The 100 unit dose may be preferable due to similar efficacy with reduced costs and adverse effects.",
keywords = "onabotulinum toxin A, prostatic hyperplasia",
author = "Crawford, {E. David} and Kathryn Hirst and Kusek, {John W.} and Donnell, {Robert F.} and Kaplan, {Steven A.} and McVary, {Kevin T.} and Mynderse, {Lance A.} and Claus Roehrborn and Smith, {Christopher P.} and Reginald Bruskewitz",
year = "2011",
month = "9",
doi = "10.1016/j.juro.2011.04.062",
language = "English (US)",
volume = "186",
pages = "965--970",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Effects of 100 and 300 units of onabotulinum toxin A on lower urinary tract symptoms of benign prostatic hyperplasia

T2 - A phase II randomized clinical trial

AU - Crawford, E. David

AU - Hirst, Kathryn

AU - Kusek, John W.

AU - Donnell, Robert F.

AU - Kaplan, Steven A.

AU - McVary, Kevin T.

AU - Mynderse, Lance A.

AU - Roehrborn, Claus

AU - Smith, Christopher P.

AU - Bruskewitz, Reginald

PY - 2011/9

Y1 - 2011/9

N2 - Purpose: We conducted a 2-stage, multicenter, double-blind, randomized phase II clinical trial of 100 and 300 unit doses of onabotulinum toxin A to treat the lower urinary tract symptoms of benign prostatic hyperplasia. Materials and Methods: Men 50 years old or older with clinically diagnosed benign prostatic hyperplasia, American Urological Association symptom index 8 or greater, maximum urinary flow rate less than 15 ml per second, voided volume 125 ml or greater, and post-void residual 350 ml or less were randomized to prostatic transrectal injection of 100 or 300 units of onabotulinum toxin A. The primary outcome was at least 30% improvement from baseline to 3 months in American Urological Association symptom index and/or maximum urinary flow rate and safety. The men were followed for 12 months. Results: A total of 134 men were randomized and treated (68 with 100 units, 66 with 300 units), with 131 assessed at 3 months and 108 assessed at 12 months. Each dose met the 3-month primary outcome criteria. In the 100 unit arm the mean baseline American Urological Association symptom index of 18.8 decreased by 7.1 and 6.9 at 3 and 12 months, respectively. In the 300 unit arm the baseline of 19.5 decreased by 8.9 and 7.1, respectively. In the 100 unit arm the mean baseline maximum urinary flow rate of 10.0 ml per second increased by 2.5 and 2.2, respectively, and in the 300 unit arm the baseline of 9.6 increased by 2.6 and 2.3, respectively. Conclusions: The intraprostatic injection of 100 or 300 units of onabotulinum toxin A passed predetermined criteria for treatment efficacy and safety, and a randomized trial with either dose is warranted. The 100 unit dose may be preferable due to similar efficacy with reduced costs and adverse effects.

AB - Purpose: We conducted a 2-stage, multicenter, double-blind, randomized phase II clinical trial of 100 and 300 unit doses of onabotulinum toxin A to treat the lower urinary tract symptoms of benign prostatic hyperplasia. Materials and Methods: Men 50 years old or older with clinically diagnosed benign prostatic hyperplasia, American Urological Association symptom index 8 or greater, maximum urinary flow rate less than 15 ml per second, voided volume 125 ml or greater, and post-void residual 350 ml or less were randomized to prostatic transrectal injection of 100 or 300 units of onabotulinum toxin A. The primary outcome was at least 30% improvement from baseline to 3 months in American Urological Association symptom index and/or maximum urinary flow rate and safety. The men were followed for 12 months. Results: A total of 134 men were randomized and treated (68 with 100 units, 66 with 300 units), with 131 assessed at 3 months and 108 assessed at 12 months. Each dose met the 3-month primary outcome criteria. In the 100 unit arm the mean baseline American Urological Association symptom index of 18.8 decreased by 7.1 and 6.9 at 3 and 12 months, respectively. In the 300 unit arm the baseline of 19.5 decreased by 8.9 and 7.1, respectively. In the 100 unit arm the mean baseline maximum urinary flow rate of 10.0 ml per second increased by 2.5 and 2.2, respectively, and in the 300 unit arm the baseline of 9.6 increased by 2.6 and 2.3, respectively. Conclusions: The intraprostatic injection of 100 or 300 units of onabotulinum toxin A passed predetermined criteria for treatment efficacy and safety, and a randomized trial with either dose is warranted. The 100 unit dose may be preferable due to similar efficacy with reduced costs and adverse effects.

KW - onabotulinum toxin A

KW - prostatic hyperplasia

UR - http://www.scopus.com/inward/record.url?scp=80051552892&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051552892&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2011.04.062

DO - 10.1016/j.juro.2011.04.062

M3 - Article

C2 - 21791356

AN - SCOPUS:80051552892

VL - 186

SP - 965

EP - 970

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 3

ER -